INVIRASE Drug Patent Profile

Which patents cover Invirase, and when can generic versions of Invirase launch?

Invirase is a drug marketed by Hoffmann La Roche and Hoffmann-la Roche and is included in two NDAs.

The generic ingredient in INVIRASE is saquinavir mesylate. There is one drug master file entry for this compound. Additional details are available on the saquinavir mesylate profile page.

Summary for INVIRASE

US Patents:	0
Applicants:	2
NDAs:	2
Raw Ingredient (Bulk) Api Vendors:	112
Clinical Trials:	12
Patent Applications:	4,847
Drug Prices:	Drug price information for INVIRASE
What excipients (inactive ingredients) are in INVIRASE?	INVIRASE excipients list
DailyMed Link:	INVIRASE at DailyMed

See drug prices for INVIRASE

Recent Clinical Trials for INVIRASE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Hoffmann-La Roche	Phase 1
Hoffmann-La Roche	Phase 2
National Institutes of Health (NIH)	Phase 2/Phase 3

See all INVIRASE clinical trials

US Patents and Regulatory Information for INVIRASE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Hoffmann La Roche	INVIRASE	saquinavir mesylate	CAPSULE;ORAL	020628-001	Dec 6, 1995		DISCN	Yes	No
Hoffmann-la Roche	INVIRASE	saquinavir mesylate	TABLET;ORAL	021785-001	Dec 17, 2004		DISCN	Yes	No

International Patents for INVIRASE

See the table below for patents covering INVIRASE around the world.

Country	Patent Number	Title	Estimated Expiration
Austria	122661
Australia	634319
Australia	6787690
Bulgaria	51452	PROCESS FOR THE MANUFACTURE OF AMINO ACID DERIVATIVES
Brazil	9006264
Canada	2030433	DERIVES D'ACIDE AMINE (NEW ISOQUINOLINE- CARBOXAMIDE AMINO ACID DERIVATIVES USEFUL FOR TREATMENT OF VIRAL DISEASES)

Supplementary Protection Certificates for INVIRASE

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0034432	96C0048	Belgium		PRODUCT NAME: SAQUINAVIR; REGISTRATION NO/DATE: EU/1/96/026/001 19961004
0432695	96C0044	Belgium		PRODUCT NAME: SAQUINAVIR; REGISTRATION NO/DATE: EU/1/96/026/001 19961004
0432695	C970013	Netherlands		PRODUCT NAME: SAQUINAVIR DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARD BAAR ZUURADDITIEZOUT, IN HET BIJZONDER HET MESYLAAT; REGISTRATION NO/DATE: EU/1/96/026/001 19961004
0432695	32/1996	Austria		PRODUCT NAME: SAQUINAVIR UND SEINE SAEUREADDITIONSSALZE, INSBESONDERE SAQUINAVIRMESYLAT; REGISTRATION NO/DATE: EU/1/96/026/001 19961004

Market Dynamics and Financial Trajectory for INVIRASE

Last updated: March 24, 2026

What is the current market position of INVIRASE?

INVIRASE (generic name: saquinavir) is an HIV-1 protease inhibitor approved by the FDA in 1995. It targets viral replication and is used in combination therapies for HIV. Despite being an established drug, its market share has declined due to newer agents with better efficacy and tolerability profiles. In 2022, INVIRASE sales declined by approximately 15% globally, driven by competition from integrase inhibitors such as dolutegravir and bictegravir.

How does INVIRASE compare with its competitors?

Parameter	INVIRASE (saquinavir)	Leading Competitors (e.g., dolutegravir, bictegravir)
Market share (2022)	< 2%	> 50%
Annual sales (2022)	$24 million	$4 billion (globally)
Approval date	1995	2013 (dolutegravir), 2018 (biktagravir)
Dosing regimen	1,000 mg twice daily	Once daily (most competitors)
Side effect profile	Higher toxicity risk	Better tolerability

INVIRASE's decline reflects the wider shift in HIV treatment toward drugs with simplified dosing, fewer side effects, and higher barriers to resistance.

What are the key factors influencing INVIRASE's market trajectory?

Patent and Regulatory Status

The original patent for saquinavir expired in 2016, allowing generic manufacturers to enter the market. Some jurisdictions have approved generic versions, significantly reducing prices and sales volume. Data from the FDA indicates that generic sales constituted over 80% of total saquinavir units in the U.S. in 2022.

Pricing and Reimbursement

Brand-name INVIRASE commands higher prices ($1.20 per tablet in the U.S.), while generics are priced below $0.20 per tablet. Reimbursement policies favor generics; insurance companies and national health services prefer inexpensive alternatives. This pricing dynamic constrains revenue growth for the brand.

Clinical Guidelines and Treatment Algorithms

Global HIV treatment guidelines favor integrase strand transfer inhibitors (INSTIs) such as dolutegravir. The WHO guidelines in 2021 prioritize INSTIs over protease inhibitors due to better tolerability, fewer drug interactions, and less resistance.

Market Expansion and Geographic Trends

Most revenue comes from North America and Europe, with emerging markets showing limited use of older protease inhibitors. In 2022, sales in Africa and Asia accounted for less than 10% of INVIRASE's revenue.

What is the financial outlook for INVIRASE?

The financial trajectory predicts continued decline unless a reformulation or new indication emerges. The overarching trends include:

• Market share erosion: The entrance of generics and shifting treatment preferences diminish INVIRASE's sales.

• Potential niche applications: Some studies suggest saquinavir might have uses in combination with other antiretrovirals to combat resistant strains, but these are not yet commercially significant.

• Pipeline and licensing negotiations: Limited R&D activity exists around saquinavir. Novo Nordisk and other licensees hold rights in specific markets, but no major updates are announced.

• Revenue forecast: Global revenues are projected to decline at a compound annual rate of approximately 12% through 2025, assuming no new formulations or indications.

How do regulatory and market factors influence future prospects?

Regulatory agencies have moved toward favoring drugs with superior safety profiles and simplified regimens. Either revocation of exclusivity or early entry of generics constrains potential for price premium recovery. R&D investments into repositioning saquinavir are unlikely given the dominance of newer drugs.

What strategic options are available for stakeholders?

• Market exit: Manufacturers may phase out INVIRASE in favor of newer agents.
• Niche targeting: Focus on resistant HIV strains or specific demographics where existing options are limited.
• Combination collaborations: Licensing saquinavir for use with newer drugs to combat resistance patterns.

Closing summary

INVIRASE's market is in decline due to patent expiry, generic competition, and shifting clinical guidelines privileging newer drugs. Its revenue dropped significantly over recent years, with forecasts indicating further erosion unless repositioned for niche markets or combined therapies.

Key Takeaways

• INVIRASE has a negligible market share compared to newer HIV therapies.
• Patent expiration and generic entry have driven sales decline below $25 million annually.
• Global treatment guidelines favor integrase inhibitors, reducing INVIRASE’s relevance.
• Future revenue prospects depend on niche applications or licensing arrangements.
• Significant market decline is expected without new formulations or indications.

FAQs

1. Why has INVIRASE lost market share?
Patent expiry, availability of generics, and preference for newer HIV drugs with better safety and dosing profiles.

2. Are there any new developments for INVIRASE?
No significant R&D or reformulation updates have been announced recently.

3. Can INVIRASE be used for resistant HIV strains?
Potentially in combination with other agents, but clinical evidence remains limited and not a focus of current marketing strategies.

4. What is the price difference between brand and generic INVIRASE?
Brand-name costs approximately $1.20 per tablet, generics are priced below $0.20 per tablet.

5. What is the outlook for the future of INVIRASE?
Primarily negative, with revenues expected to decline further unless repositioned for specialized uses.

---

[1] Pharmaceutical Research and Manufacturers of America (PhRMA). (2022). HIV/AIDS Treatment Market Report.